Skip to main content

Astrazeneca Plc ADR(AZN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low75.75
Day High76.41
Open:76.26
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
the globe and mail

Drugmaker AstraZeneca announces dividend hike ahead of vote on CEO’s pay package

AstraZeneca said it will pay a dividend of $3.10 per share this year, taking into account other capital allocation priorities as well as previously announced acquisitions and business development
Barchart
Stocks Retreat as Persistent Inflation Dents Fed Rate-Cut Hopes
Motley Fool
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript
Barchart
Stocks Lower on Tech Stocks Weakness and Stagflation Fears
Motley Fool
4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Barchart
Stock Indexes Rise in Afternoon Trade
Barchart
Stocks Slightly Higher as US Mar PPI Climbs Less Than Expected
BayStreet.ca
Biotech Breakthroughs Spearhead Fight Against Rising Breast Cancer Cases
Motley Fool
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
Barchart
Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock
SYNDTGAM
AstraZeneca to buy Amolyt Pharma for US$1.05-billion to boost rare-disease portfolio
Barchart
Beyond the GRANOLAS: JPMorgan Picks 3 Top Stocks to Bet on Europe
Motley Fool
Got $200? 2 Dividend Stocks to Buy and Hold Forever
Motley Fool
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
Motley Fool
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
Barchart
Stocks Settle Mixed Ahead of Tuesday’s U.S. CPI Report
Motley Fool
Got $5,000? These 3 Stocks Are Near Their 52-Week Lows and Are Underrated Buys
Barchart
S&P 500 and Nasdaq 100 Post Record Highs on Solid Earnings
Motley Fool
AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript
Barchart
Higher Bond Yields Weigh on Stocks But Chip Stocks Provide Support
BayStreet.ca
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer
Motley Fool
History Says the Nasdaq Will Keep Soaring in 2024. Here's the Surprising Megacap Stock Wall Street Thinks Will Be the Biggest Winner.
Barchart
2 Mega-Cap Pharma Stocks to Buy for More Upside

Profile

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.